潰瘍性大腸炎治療薬の世界市場2016-2020

◆英語タイトル:Global Ulcerative Colitis Market 2016-2020
◆商品コード:IRTNTR8159
◆発行会社(調査会社):Technavio
◆発行日:2016年5月2日
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、潰瘍性大腸炎治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、潰瘍性大腸炎治療薬の世界市場規模及び予測、剤形別分析、投与経路(ROA)別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、医療費償還シナリオ、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Ulcerative Colitis
Ulcerative colitis is a type of inflammatory bowel disease (IBD) that affects the colon and rectum. Inflammation and ulcers are formed in the innermost lining of the colon and rectum, resulting in the production of pus and mucous. Based on the extent of inflammation and the location, ulcerative colitis can be of different types: ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Abdominal cramps, diarrhea, and rectal bleeding are among the common symptoms observed in individuals with the disease. Medications such as 5-aminosalicylates, steroids, purine analogs, immunomodulators, and biologics are used to treat the disease.

Technavio’s analysts forecast the global ulcerative colitis market to grow at a CAGR of 6.6% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global ulcerative colitis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used to treat ulcerative colitis.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Ulcerative Colitis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• Janssen Biotech
• Merck
• Takeda Pharmaceuticals

[Other prominent vendors]
• Abbott
• Ajinomoto Pharmaceuticals
• Amgen
• Arena Pharmaceuticals
• AstraZeneca
• Astellas Pharma
• Avaxia Biologics
• BioLineRx
• Celgene
• Cosmo Pharmaceuticals
• Eisai
• Ferring Pharmaceuticals
• Galapagos
• Genentech
• Gilead Sciences
• GlaxoSmithKline
• Hutchison Medi Pharma
• Immune Pharmaceuticals
• InDex Pharmaceuticals
• Kaken Pharmaceutical
• Kissei Pharmaceutical
• Kyowa Hakko Kirin
• Lipid Therapeutics
• Meda
• Mitsubishi Tanabe
• Mochida Pharmaceutical
• Morphotek
• Nestlé
• Pfizer
• Procter & Gamble
• Qu Biologics
• Receptos
• Salix Pharmaceuticals
• Shield Therapeutics
• Shire Pharmaceuticals
• Sterna Biologicals
• Tillotts Pharma
• TopiVert
• UCB
• Zeria Pharmaceutical

[Market driver]
• Increase in patient assistance programs
• For a full, detailed list, view our report

[Market challenge]
• Patent expiries
• For a full, detailed list, view our report

[Market trend]
• Rising use of biologics
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Etiology
• Epidemiology
• Symptoms
• Diagnosis and testing
• Treatment
• Prognosis
• Economic burden
• Reimbursement scenario

PART 06: Pipeline analysis
• Z-206
• MD-0901
• TP05
• Stelara
• Etrolizumab
• Xeljanz
• HMPL-004
• Kappaproct
• AJG511
• AJM300

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by molecule type
• Biologics
• Small molecules
• Biologics segment in ulcerative colitis drugs market
• Small molecules segment in ulcerative colitis drugs market

PART 09: Market segmentation by dosage form
• Solid
• Liquid

PART 10: Market segmentation by route of administration
• Oral
• Parenteral

PART 11: Geographical segmentation
• Global ulcerative colitis drugs market by geography 2015-2020
• Ulcerative colitis drugs market in Americas
• Ulcerative colitis drugs market in EMEA
• Ulcerative colitis drugs market in APAC

PART 12: Market drivers
• Increase in patient assistance programs
• High unmet needs
• Tentative approval of candidates in pipeline

PART 13: Impact of drivers

PART 14: Market challenges
• High cost of drugs
• Patent expiries
• Adverse effects of drugs
• Unknown disease etiology

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Growing public awareness
• Rising use of biologics
• Emergence of biosimilars
• Strategic alliances

PART 17: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• AbbVie
• Janssen Biotech
• Merck
• Takeda Pharmaceuticals
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Causes of ulcerative colitis
Exhibit 03: Symptoms of ulcerative colitis
Exhibit 04: Diagnostic approach for ulcerative colitis
Exhibit 05: Treatment options for ulcerative colitis
Exhibit 06: Treatment guidelines of ulcerative colitis based on severity
Exhibit 07: Surgical procedures to treat ulcerative colitis
Exhibit 08: Global ulcerative colitis drugs market: Pipeline portfolio
Exhibit 09: Global ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 10: Snapshot of global ulcerative colitis drugs market
Exhibit 11: Five forces analysis
Exhibit 12: Global ulcerative colitis drugs market by molecule type
Exhibit 13: Global ulcerative colitis drugs market by molecule type 2015
Exhibit 14: Biologics segment in ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 15: Small molecules segment in ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 16: Global ulcerative colitis drugs market by dosage form
Exhibit 17: Global ulcerative colitis drugs market by route of administration
Exhibit 18: Global ulcerative colitis drugs market segment by geography 2015
Exhibit 19: Ulcerative colitis drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 20: Ulcerative colitis drugs market in Americas 2015-2020 ($ billions)
Exhibit 21: Ulcerative colitis drugs market in EMEA 2015-2020 ($ billions)
Exhibit 22: Ulcerative colitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Global ulcerative colitis drugs market share analysis 2015
Exhibit 26: YoY revenue comparison of top drugs for ulcerative colitis 2011-2014 ($ millions)
Exhibit 27: AbbVie: Product segmentation by revenue 2014
Exhibit 28: AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 29: AbbVie: Geographical segmentation by revenue 2014
Exhibit 30: AbbVie: YoY growth and revenue of Humira 2012-2014 ($ billions)
Exhibit 31: AbbVie: Key takeaways
Exhibit 32: Janssen Biotech: YoY growth and revenue of Remicade 2012-2014 ($ millions)
Exhibit 33: Janssen Biotech: YoY growth and revenue of Simponi/Simponi ARIA 2012-2014 ($ millions)
Exhibit 34: Janssen Biotech: Key takeaways
Exhibit 35: Merck: Business segmentation by revenue 2014
Exhibit 36: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 37: Merck: Geographical segmentation by revenue 2014
Exhibit 38: Merck: YoY growth and revenue of Remicade 2012-2014 ($ millions)
Exhibit 39: Merck: YoY growth and revenue of Simponi 2012-2014 ($ millions)
Exhibit 40: Merck: Key takeaways
Exhibit 41: Takeda Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 42: Takeda Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 44: Takeda Pharmaceuticals: Key takeaways



【掲載企業】

AbbVie, Janssen Biotech, Merck, Takeda Pharmaceuticals, Abbott, Ajinomoto Pharmaceuticals, Amgen, Arena Pharmaceuticals, AstraZeneca, Astellas Pharma, Avaxia Biologics, BioLineRx, Celgene, Cosmo Pharmaceuticals, Eisai, Ferring Pharmaceuticals, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lipid Therapeutics, Meda, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Nestlé, Pfizer, Procter & Gamble, Qu Biologics, Receptos, Salix Pharmaceuticals, Shield Therapeutics, Shire Pharmaceuticals, Sterna Biologicals, Tillotts Pharma, TopiVert, UCB, Zeria Pharmaceutical.

【レポートのキーワード】

潰瘍性大腸炎、炎症性腸疾患、潰瘍性大腸炎治療薬、医薬品、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[潰瘍性大腸炎治療薬の世界市場2016-2020] (コード:IRTNTR8159)販売に関する免責事項を必ずご確認ください。
★調査レポート[潰瘍性大腸炎治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆